cAMP signalling in osteoimmune regulation: mechanistic determinants and translational evidence

Bone remodelling and repair depend on interactions amongst skeletal, stromal and immune cells, and disruption of these interactions contributes to bone disease. Cyclic adenosine monophosphate (cAMP) signalling transduces endocrine, inflammatory and mechanical cues across osteoblast-lineage cells, osteocytes, osteoclast-lineage cells and immune cells. However, elevated intracellular cAMP does not produce a uniform skeletal response. Receptor identity, the spatial and temporal organisation of cAMP signals, the identity and differentiation state of the responding cell, and downstream effector engagement together influence bone formation, osteoclast differentiation and immune-cell responses. Protein kinase A (PKA) mediates several well-characterised responses, whereas exchange proteins directly activated by cAMP (EPACs) can mediate distinct downstream effects. This review compares the evidence for these mechanisms, distinguishing receptor-associated observations and cAMP elevation from effects experimentally shown to depend on PKA or EPAC. The discussion focuses on osteoporosis, inflammatory bone destruction, including periodontitis-associated alveolar bone loss, and experimental strategies for local bone regeneration. Evidence directly linking cAMP signalling to osteoimmune mechanisms in osteoarthritis and tumour-associated bone disease is less complete. Parathyroid hormone 1 receptor (PTH1R) agonists have established antifracture efficacy in osteoporosis, but this validates receptor-directed treatment rather than isolated PKA activation. Phosphodiesterase 4 (PDE4) inhibition has clinical anti-inflammatory efficacy in psoriatic arthritis, whereas protection against structural bone damage remains unestablished. Adenosine receptor modulation and local or bone-targeted delivery are supported mainly by preclinical skeletal evidence. Further translation will require identification of the responding cell populations, direct assessment of downstream effector involvement and demonstration of benefit using disease-relevant skeletal outcomes. Overall, cAMP signalling is best understood as a context-dependent regulatory network rather than a uniformly anabolic or anti-resorptive pathway.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.1982079
Primary Topic
Bone Metabolism and Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

cAMP signalling in osteoimmune regulation: mechanistic determinants and translational evidence

Xiaoyan Guan, Chengcheng Liao, Yi Deng, Shanshan Zhang et al.
Frontiers in Immunology
Bone Metabolism and Diseases
article

cAMP signalling in osteoimmune regulation: mechanistic determinants and translational evidence

Xiaoyan Guan, Chengcheng Liao, Yi Deng, Shanshan Zhang, Jun Cai, Wen Zhao, Linlin Xiao, Jianguo Liu
article en

Abstract

Bone remodelling and repair depend on interactions amongst skeletal, stromal and immune cells, and disruption of these interactions contributes to bone disease. Cyclic adenosine monophosphate (cAMP) signalling transduces endocrine, inflammatory and mechanical cues across osteoblast-lineage cells, osteocytes, osteoclast-lineage cells and immune cells. However, elevated intracellular cAMP does not produce a uniform skeletal response. Receptor identity, the spatial and temporal organisation of cAMP signals, the identity and differentiation state of the responding cell, and downstream effector engagement together influence bone formation, osteoclast differentiation and immune-cell responses. Protein kinase A (PKA) mediates several well-characterised responses, whereas exchange proteins directly activated by cAMP (EPACs) can mediate distinct downstream effects. This review compares the evidence for these mechanisms, distinguishing receptor-associated observations and cAMP elevation from effects experimentally shown to depend on PKA or EPAC. The discussion focuses on osteoporosis, inflammatory bone destruction, including periodontitis-associated alveolar bone loss, and experimental strategies for local bone regeneration. Evidence directly linking cAMP signalling to osteoimmune mechanisms in osteoarthritis and tumour-associated bone disease is less complete. Parathyroid hormone 1 receptor (PTH1R) agonists have established antifracture efficacy in osteoporosis, but this validates receptor-directed treatment rather than isolated PKA activation. Phosphodiesterase 4 (PDE4) inhibition has clinical anti-inflammatory efficacy in psoriatic arthritis, whereas protection against structural bone damage remains unestablished. Adenosine receptor modulation and local or bone-targeted delivery are supported mainly by preclinical skeletal evidence. Further translation will require identification of the responding cell populations, direct assessment of downstream effector involvement and demonstration of benefit using disease-relevant skeletal outcomes. Overall, cAMP signalling is best understood as a context-dependent regulatory network rather than a uniformly anabolic or anti-resorptive pathway.

Frontiers in ImmunologyVol. 17
Zunyi Medical University (CN), Affiliated Hospital of Zunyi Medical College (CN)
Health Commission of Guizhou Province, Guizhou Science and Technology Department, Department of Education of Guizhou Province
Good health and well-being
Bone Metabolism and Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon